Asogisfe brinda este Servicio a sus Asociados.
Asogisfe: Una construcción colectiva y solidaria.
Safety and immunogenicity of an rAd26 and rAd5
vector-based heterologous prime-boost COVID-19 vaccine
in two formulations: two open, non-randomised phase 1/2
studies from Russia
Denis Y Logunov*,
https://drive.google.com/file/d/1ugSd0gjB_3YCTLqujHFSMyyKdLBpHUxx/view?usp=sharing
No hay comentarios:
Publicar un comentario